Navigation Links
Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis
Date:8/12/2008

iginating in the atria. It has been estimated that there are 89,000 new cases of PSVT per year and approximately 570,000 persons overall with PSVT in the United States alone.

Currently, adenosine is the only approved treatment for PSVT in the U.S. Duska believes that the initial dose of ATPace will be significantly more efficacious than the initial labeled dose of adenosine in terminating PSVT. While both adenosine triphosphate and adenosine inhibit atrio-ventricular nodal conduction, adenosine triphosphate is believed to have dual inhibitory action; one mediated by adenosine, the product of its rapid enzymatic degradation, and the other, a triggered vagal reflex. Vagal maneuvers aimed at enhancing vagal tone to the heart, and thereby suppressing atrio-ventricular nodal conduction, have been clinically used to terminate tachycardia. Injectable formulations of adenosine triphosphate have been approved in Europe for over 50 years as safe and efficacious treatments for PSVT. Duska has established its own safety database for ATPace, which was obtained in its Phase 1 and 2 clinical trials, and has obtained more than 1,000 patients records from other clinical trials.

About Duska Therapeutics, Inc.

Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Duska is developing a portfolio of investigational medicines, two of which are in late stages of clinical testing. Duska's ATPace(TM) is expected to enter a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Duska's CDP-1050 is expected to commence a Phase 2 clinical trial for the
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Duska Therapeutics Plans 505(b)(2) NDA Filing Route for ATPace(TM)
2. Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
3. Prime Therapeutics Receives TIPPS Certification
4. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
5. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
6. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
7. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
8. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
9. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
10. Prime Therapeutics Announces URAC Accreditation
11. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2015)... With the FCPX LUT B&W pack from Pixel ... quickly and easily add desaturated color grades to footage. A ... for modifying an image. The LUT changes every pixel's color ... comes with 60 black and white CUBE LUT files. , ... white films. With the FCPX LUT B&W Loader from ...
(Date:4/26/2015)... 2015 In an article published last ... the head-neck biomechanics occurring during the use of handheld electronic ... to determine that use of a tablet increases mechanical demand ... times - more than when the neck is in a ... study, but pointing out the potential hazards of overuse of ...
(Date:4/25/2015)... (PRWEB) April 26, 2015 Diversified ... based integrative healthcare event. The Integrative Healthcare Symposium ... October 23-24, 2015 at the Sheraton Parkway Toronto ... Canada is one of the most anticipated events ... relevant, evidenced-based CME program. The event aims to ...
(Date:4/25/2015)... York (PRWEB) April 25, 2015 ... for vaginal mesh lawsuits filed against C.R. Bard, ... District Court, Southern District of West Virginia. According ... Scheduling Conference was convened that day, after certain ... Long Form Complaint. The Order directed that any ...
(Date:4/25/2015)... 2015 Gardant Management Solutions will ... and operations, and sales and marketing at the ... to be held from April 29 through May ... the largest eldercare association in Illinois. The statewide ... older adults, including senior housing, assisted living and ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios, a FCPX Effects Developer, Announced the Release of FCPX LUT B&W 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Integrative Healthcare Event launching in Canada 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Gardant Management Solutions Staff Shares Operational Expertise 2
... THURSDAY, June 9 (HealthDay News) -- With record-breaking heat searing ... and with little relief in sight -- health experts are ... oppressive temperatures and humidity. "The elderly, young children and ... taking certain medications, especially antidepressants, are most at risk ...
... new study published today in the inaugural issue of the ... by tracking pharmacy purchases of anti-Parkinson drugs they could estimate ... population. The study identified a sharp rise in PD prevalence ... which warrants further investigation. Surprisingly, much of the world ...
... Steven Reinberg HealthDay Reporter , THURSDAY, June 9 ... treated in hospital emergency rooms for injuries sustained in bathrooms ... in the June 10 issue of the U.S. Centers ... Report , indicate that most of these injuries -- 80 ...
... In a study published today in the Clinical ... Kennedy Krieger Institute found differences in the brain development ... Results showed the region of the brain important for ... than in typically developing children. Novel for its use ...
... Reporter , WEDNESDAY, June 8 (HealthDay News) -- Women offered ... time they,re having a uterine aspiration due to miscarriage or ... women offered one later on, new research suggests. The ... inserted immediately after a uterine aspiration is higher than it ...
... gene linked to emphysema also can be a factor for ... Center research indicates. Smoking was the only known risk factor ... mice bred to have the human gene pleiomorphic adenoma gene-like ... lung cancer at rates as high as one in every ...
Cached Medicine News:Health News:Record Temperatures Posing Health Risks in U.S. 2Health News:Record Temperatures Posing Health Risks in U.S. 3Health News:New method for measuring Parkinson's disease prevalence reveals sharp increase in Israel 2Health News:Bathroom Injuries a Little-Known Problem 2Health News:Brain imaging study of preschoolers with ADHD detects brain differences linked to symptoms 2Health News:It's Safe to Get IUD Right After Abortion, Miscarriage: Study 2Health News:It's Safe to Get IUD Right After Abortion, Miscarriage: Study 3Health News:UT Southwestern research uncovers genetic link between emphysema, lung cancer 2
(Date:4/23/2015)...  AbbVie (NYSE: ABBV ) has announced that ... its New Drug Application (NDA) and granted priority review ... of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The ... genotype 4 (GT4) hepatitis C virus (HCV) infection. ... being evaluated by the FDA for patients in ...
(Date:4/23/2015)... , April 23, 2015 Once again, ... strengthening our commitment to patient safety. BeaconMedaes, ... fight against infectious disease. The next generation ... Medical gas sensors are now mounted in the assembly, ... need to open ceiling tiles potentially releasing dust spores ...
(Date:4/23/2015)... FRANCISCO , April 23, 2015 Nektar Therapeutics ... the first quarter ended March 31, 2015 on Thursday, April ... Howard Robin , president and chief executive officer, will host ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... the conference call can be accessed through a link that ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company ... from its consumer trial with Allumera™, a breakthrough cosmetic ... The RevitAll study was performed with a standard ... Allumera™ improves skin appearance, when compared to exposure by ...
... Inc. (Hologic or the Company) (Nasdaq: ... of premium diagnostics products, medical imaging systems and ... of women, announced today the U.S. Food and ... Makena™ (hydroxyprogesterone caproate injection), formerly known as Gestiva™. ...
Cached Medicine Technology:Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 2Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 3Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 4FDA Approves Hologic's Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical 2
... includes everything from the care package ... Spare Fluorescent Bulb, additional Vibratome Feather ... and a Specimen Tray. ... 1/2" speciment mounts, replacement rotating mounts, ...
... The Specimen Tray accessory fits inside the ... removable working area for tissue sectioning. Specimens ... specimen tray. This is a great option ... an expensive buffer, or wish to utilize the ...
... inside the existing black Vibratome bath. This ... buffer and ice kept in the original black ... has round mounting disks that can be easily ... bath surface are marked with degrees of rotation ...
... This unit provides a convenient reservoir of cooling ... operated for an extended period of time or in ... nearby to cool the hot side of the thermoelectric ... of water, which is adequate to run the 900R ...
Medicine Products: